Dermatological Burns, Scars and Ulcers Drug Development Pipeline Review, 2018 – ResearchByMarkets

Dermatological Burns, Scars and Ulcers Drug Development Pipeline Review, 2018

Summary

This report provides an overview of the pipeline landscape for dermatological burns, scars and ulcers. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for pressure ulcers, venous leg ulcers, burns and scars, and features dormant and discontinued products.

A pressure ulcer is an injury that breaks down the skin and underlying tissue. The parts of the body most at risk of developing pressure ulcers are those that are not covered by a large amount of body fat and are in direct contact with a supporting surface (bed or a wheelchair). Causes include continuous pressure, friction and shear. Treatment includes antibiotics and nutrition. There are six products in development for this indication.

Venous leg ulcers develop when persistently high blood pressure in the veins of the legs (venous hypertension) causes damage to the skin, which eventually breaks down and forms an ulcer. Symptoms include swollen ankles filled with fluid that temporarily hold the imprint of a finger when pressed (known as pitting edema), discoloration and darkening of the skin around the ulcer (known as hemosiderosis), hardened skin around the ulcer, which may make the leg feel hard (known as lipodermatosclerosis), and small, smooth areas of white skin, which may have tiny red spots (known as atrophie blanche). There are 14 products in development for this indication.

A burn refers to damage to the body’s tissues caused by heat, chemicals, electricity, sunlight or radiation. Symptoms include pain, which increases with each degree of burn, red and swollen skin, blisters, and charred and blackened skin. Treatment includes antibiotics and pain relievers. There are 32 products in development for this indication.

A scar is a permanent patch of skin that grows over a wound. Scars occur at the site of tissue damage and appear as firm red-to-purple fibrous tissue that over time usually becomes flatter and lighter in color. There are 20 products in development for this indication.

Molecular targets acted on by products in development for dermatological burns, scars and ulcers include integrins, interleukins and growth factors. Companies operating in this pipeline space include MediWound, Aegle Therapeutics and NovaLead Pharma.

REQUEST A SAMPLE REPORT:
https://www.researchbymarkets.com/sample-request/36385

Scope

– Which companies are the most active within each pipeline?
– Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
– To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
– What are the most important R&D milestones and data publications to have happened in this disease area?

Reasons to buy

– Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
– Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication and a comprehensive picture of recent updates and milestones for each
– Analyze the companies, institutions and universities currently operating in the pipeline and the products being fielded by each of these
РUnderstand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration 

Companies Mentioned: 
Abzena Plc
AlgiPharma AS
Alliance Pharma Plc
Altacor Ltd
Amarantus Bioscience Holdings Inc
BirchBioMed Inc
CardioVascular BioTherapeutics Inc
CFM Pharma Holding BV
Cotinga Pharmaceuticals Inc
CytoTools AG
Daval International Ltd
Destiny Pharma Plc
Energenesis Biomedical Co Ltd
EyeGene Inc
Factor Therapeutics Ltd
FirstString Research Inc
GangaGen Inc
Izun Pharmaceuticals Corp
Kringle Pharma Inc
Madam Therapeutics BV
MallInckrodt Plc
MediWound Ltd
MimeTech Srl
Moerae Matrix Inc
NovaLead Pharma Pvt Ltd
Phagelux Inc
Pharmaxis Ltd
Promore Pharma AB
Resolys Bio Inc
RXi Pharmaceuticals Corp
Se-cure Pharmaceuticals Ltd
Synedgen Inc
Therapure Biopharma Inc
USV Pvt Ltd

Buy this report via Credit Card/Paypal or Wire Transfer:
https://www.researchbymarkets.com/paynow/36385

Contact Us:
ResearchByMarkets.com
Ritesh Tiwari, Director
enquiry@researchbymarkets.com
USA: +1-800-416-3124
https://www.researchbymarkets.com/aboutus

Ritesh Tiwari is the Founder of Research By Markets. He has more than 7 years experience in the Market Research industry and a total experience spanning 18+ years. His core experience is in Sales and International Recruitments. Ritesh is a big foodie and a huge football fan, supporting Manchester United (EPL) and FC Barcelona (La Liga). He hardly misses watching any matches when these teams are playing. Get in touch with Ritesh via: enquiry@researchbymarkets.com *Industry Press Release is a part of Research By Markets.